ME02678B - Antitijela na ox-40 i postupci njihove primjene - Google Patents
Antitijela na ox-40 i postupci njihove primjeneInfo
- Publication number
- ME02678B ME02678B MEP-2017-84A MEP8417A ME02678B ME 02678 B ME02678 B ME 02678B ME P8417 A MEP8417 A ME P8417A ME 02678 B ME02678 B ME 02678B
- Authority
- ME
- Montenegro
- Prior art keywords
- antigen
- amino acid
- seq
- variable region
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (10)
1. Izolovano antitelo, ili njegov deo koji vezuje antigen, koje vezuje humani OX40 koji sadrži: (a) varijabilni region CDRl teškog lanca, aminokiselinske sekvence SEQ ID NO:1; (b) varijabilni region CDR2 teškog lanca, aminokiselinske sekvence SEQ ID NO:2; (e) varijabilni region CDR3 teškog lanca, aminokiselinske sekvence SEQ ID NO:3; (d) varijabilni region CDR1 lakog lanca, aminokiselinske sekvence SEQ ID NO:7; (e) varijabilni region CDR2 lakog lanca, aminokiselinske sekvence SEQ ID NO8; i (t) varijabilni region CDR3 lakog lanca, aminokiselinske sekvence SEQ ID NO:9.
2. Izolovano antitelo, ili njegov deo koji vezuje antigen, prema zahtevu 1, koje sadrži varijabilni region lakog lanca sekvence koja je najmanje 90% identična aminokiselinskoj sekvenci SEQ ID NO:10 i varijabilni region teškog lanca sekvence koja je najmanje 90% identična aminokiselinskoj sekvenci SEQ ID NO:4.
3. Izolovano antitelo, ili njegov deo koji vezuje antigen, prema bilo kom od prethodnih zahteva, gde je izolovano antitelo monoklonsko antitelo.
4. Izolovano antitelo, ili njegov deo koji vezuje antigen, prema bilo kom od prethodnih zahteva, gde je izolovano antitelo humanizovano antitelo.
5. Izolovano humanizovano antitelo ili njegov deo koji vezuje antigen, prema zahtevu 4, koje sadrži varijabilni region lakog lanca sekvence koja je najmanje 90% identična aminokiselinskoj sekvenci SEQ ID NO:11 i varijabilni region teškog lanca sekvence koja je najmanje 90% identična aminokiselinskoj sekvenci SEQ ID NO:5.
6. Izolovana nukleinska kiselina koja kodira antitelo, ili njegov deo koji vezuje antigen, prema bilo kom zahtevu od 1 do 5
7. Ćelija-domaćin koja sadrži nukleinsku kiselinu koja kodira antitelo, ili njegov deo koji vezuje antigen, prema bilo kom zahtevu od 1 do 5
8 Postupak za dobijanje antitela, ili njegovog dela koji vezuje antigen, koji uključuje gajenje ćelija-domaćina iz zahteva 7; postupak koji poželjno uključuje i dobijanje antitela, ili njegovog dela koji vezuje antigen, iz ćelija-domaćina.
9. Izolovano antitelo, ili njegov deo koji vezuje antigen, prema bilo kom zahtevu od 1 do 5, za upotrebu kao lek.
10. Izolovano antitelo, ili njegov deo koji vezuje antigen, za primenu prema zahtevu 9, gde je lek namenjen tretiranju raka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37599910P | 2010-08-23 | 2010-08-23 | |
| US38082710P | 2010-09-08 | 2010-09-08 | |
| EP11820495.7A EP2609118B1 (en) | 2010-08-23 | 2011-08-23 | Anti-ox40 antibodies and methods of using the same |
| PCT/US2011/048752 WO2012027328A2 (en) | 2010-08-23 | 2011-08-23 | Anti-ox40 antibodies and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02678B true ME02678B (me) | 2017-06-20 |
Family
ID=45724011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-84A ME02678B (me) | 2010-08-23 | 2011-08-23 | Antitijela na ox-40 i postupci njihove primjene |
Country Status (35)
| Country | Link |
|---|---|
| US (6) | US9006399B2 (me) |
| EP (2) | EP2933268B1 (me) |
| JP (2) | JP5984810B2 (me) |
| KR (2) | KR101704865B1 (me) |
| CN (2) | CN106554417B (me) |
| AP (1) | AP2013006771A0 (me) |
| AU (1) | AU2011293558B2 (me) |
| BR (2) | BR112013004266A8 (me) |
| CA (1) | CA2809089C (me) |
| CL (3) | CL2013000545A1 (me) |
| CO (1) | CO6680693A2 (me) |
| CR (1) | CR20130126A (me) |
| CY (1) | CY1118928T1 (me) |
| DK (1) | DK2609118T3 (me) |
| DO (1) | DOP2013000045A (me) |
| EA (2) | EA031849B1 (me) |
| ES (2) | ES2630328T3 (me) |
| HR (1) | HRP20170568T1 (me) |
| HU (1) | HUE031371T2 (me) |
| IL (2) | IL224886A (me) |
| LT (1) | LT2609118T (me) |
| ME (1) | ME02678B (me) |
| MX (1) | MX339964B (me) |
| MY (1) | MY171312A (me) |
| NZ (3) | NZ716369A (me) |
| PE (2) | PE20131403A1 (me) |
| PH (1) | PH12013500354B1 (me) |
| PL (1) | PL2609118T3 (me) |
| PT (1) | PT2609118T (me) |
| RS (1) | RS55952B1 (me) |
| SG (1) | SG187945A1 (me) |
| SI (1) | SI2609118T1 (me) |
| SM (1) | SMT201700185T1 (me) |
| WO (1) | WO2012027328A2 (me) |
| ZA (1) | ZA201301442B (me) |
Families Citing this family (196)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2609118T3 (pl) * | 2010-08-23 | 2017-07-31 | Board Of Regents, The University Of Texas System | Przeciwciała anty-OX40 i sposoby ich stosowania |
| EP2731677B1 (en) * | 2011-07-11 | 2018-04-18 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to ox40 and their uses |
| KR101685262B1 (ko) * | 2011-08-23 | 2016-12-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-ｏｘ４０ 항체 및 이의 사용 방법 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| DK2964638T3 (en) | 2013-03-06 | 2017-10-30 | Astrazeneca Ab | QUINAZOLIN INHIBITORS TO ACTIVATE MUTANEOUS FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR |
| NZ712903A (en) * | 2013-03-18 | 2018-07-27 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN105612175B (zh) | 2013-08-08 | 2023-05-09 | 赛腾制药 | 基于IL-15和IL-15Rαsushi结构域的调节因子 |
| KR20160137946A (ko) * | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
| CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3322443A1 (en) * | 2015-07-13 | 2018-05-23 | Yeda Research and Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| ES3040431T3 (en) * | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| RU2689162C2 (ru) | 2014-04-03 | 2019-05-24 | Огаста Юниверсити Рисерч Инститьют, Инк. | Способы повышения эффективности противоопухолевого иммунного ответа |
| MY198017A (en) | 2014-08-19 | 2023-07-26 | Merck Sharp & Dohme | Anti-tigit antibodies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| AU2015343337A1 (en) | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Assays for detecting T cell immune subsets and methods of use thereof |
| CN107109484B (zh) | 2014-11-03 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物 |
| KR20170072343A (ko) | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| MX2017006320A (es) | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| HRP20230046T1 (hr) | 2015-03-03 | 2023-03-03 | Kymab Limited | Protutijela, upotreba i postupci |
| US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| MX2017012805A (es) | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| PH12017502013B1 (en) * | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3331918A1 (en) | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| EP3331917A1 (en) | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| BR112018002436A2 (pt) * | 2015-08-04 | 2018-09-18 | Glaxosmithkline Ip Dev Ltd | tratamento de combinação de usos de métodos destes |
| WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
| TW201716084A (zh) * | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| WO2017030823A2 (en) * | 2015-08-14 | 2017-02-23 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
| MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
| CN108137684B (zh) * | 2015-10-15 | 2022-03-08 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| GB201520903D0 (en) * | 2015-11-26 | 2016-01-13 | Qbd Qs Ip Ltd | Purification method |
| EP4015537A1 (en) | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| EP3383914A4 (en) * | 2015-12-02 | 2019-10-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| CA3006963A1 (en) * | 2015-12-03 | 2017-06-08 | Ludwig Institute For Cancer Research Ltd. | Anti-ox40 antibodies and methods of use thereof |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| SG11201809560QA (en) | 2016-05-05 | 2018-11-29 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018015879A1 (en) | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CN109843916B (zh) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法 |
| CN109863170B (zh) | 2016-08-12 | 2024-08-16 | 詹森生物科技公司 | 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子 |
| CN107815465B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041119A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ox40 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| JP2020511407A (ja) * | 2016-12-01 | 2020-04-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 併用療法 |
| WO2018100534A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| PE20191403A1 (es) | 2016-12-15 | 2019-10-04 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
| WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| JP7780248B2 (ja) | 2017-01-06 | 2025-12-04 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用 |
| EP3582855A1 (en) | 2017-02-15 | 2019-12-25 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
| EP3635011A1 (en) * | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2018225034A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| JP2020533002A (ja) * | 2017-09-13 | 2020-11-19 | ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | メラニン抗体及びその使用 |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| JP2021501801A (ja) | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| CN111601883B (zh) | 2017-11-17 | 2024-06-21 | 艾欧凡斯生物治疗公司 | 由细针抽吸物和小活检物扩增til |
| WO2019106605A1 (en) | 2017-12-01 | 2019-06-06 | Board Of Regents, The University Of Texas System | Combination treatment for cancer |
| US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
| AU2018394939B2 (en) | 2017-12-29 | 2022-02-24 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| US12104172B2 (en) | 2018-01-08 | 2024-10-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific t-cells |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN110092832B (zh) * | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | 抗ox40抗体及其用途 |
| MA51875A (fr) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics Inc | Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine |
| TW202003555A (zh) * | 2018-03-07 | 2020-01-16 | 英商葛蘭素史克智慧財產發展有限公司 | 用於純化重組多肽之方法 |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| WO2019184909A1 (zh) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| MA52533A (fr) | 2018-04-27 | 2021-03-03 | Iovance Biotherapeutics Inc | Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie |
| CN114685665B (zh) * | 2018-05-11 | 2025-02-14 | 无锡药明生物技术股份有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| EP3852524B1 (en) | 2018-09-20 | 2023-06-28 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
| CA3113541A1 (en) * | 2018-09-26 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
| WO2020076977A2 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| US20230039976A1 (en) | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| KR20210091213A (ko) | 2018-11-05 | 2021-07-21 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도 |
| JP7688575B2 (ja) | 2018-11-05 | 2025-06-04 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療 |
| CN113348180B (zh) * | 2018-11-20 | 2023-05-26 | 上海开拓者生物医药有限公司 | Ox40抗体及其制备方法和应用 |
| US20220193131A1 (en) | 2018-12-19 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| WO2020160375A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| CA3134144A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Llc | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| CN114391015A (zh) | 2019-05-16 | 2022-04-22 | 斯汀塞拉股份有限公司 | 苯并[b][1,8]萘啶乙酸衍生物和使用方法 |
| CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| MA56397A (fr) | 2019-06-26 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Protéines de liaison à l'il1rap |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| US20220296705A1 (en) * | 2019-08-09 | 2022-09-22 | Riken | Combined use of artificial adjuvant vector cells and an immunostimulant |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| EP4034562B1 (en) | 2019-09-27 | 2025-10-29 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins |
| EP4048295A1 (en) | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| IL293350A (en) | 2019-11-27 | 2022-07-01 | Myst Therapeutics Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| JP7749561B2 (ja) | 2019-12-11 | 2025-10-06 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法 |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN114867749A (zh) * | 2019-12-17 | 2022-08-05 | 安进公司 | 用于疗法中的双重白介素-2/tnf受体激动剂 |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| CN113135994A (zh) * | 2020-01-19 | 2021-07-20 | 迈威(上海)生物科技股份有限公司 | 一种激活型抗ox40抗体、生产方法及应用 |
| US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| CN115427438A (zh) | 2020-02-27 | 2022-12-02 | 迈斯特治疗公司 | 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物 |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN112442121A (zh) * | 2020-08-20 | 2021-03-05 | 山东兴瑞生物科技有限公司 | Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用 |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN112957475B (zh) * | 2021-02-04 | 2022-07-22 | 李文峰 | 一种预防和或治疗肿瘤的组合物及应用 |
| CN116917273A (zh) | 2021-03-02 | 2023-10-20 | 葛兰素史克知识产权发展有限公司 | 作为dnmt1抑制剂的经取代的吡啶 |
| KR20240032711A (ko) | 2021-03-25 | 2024-03-12 | 이오반스 바이오테라퓨틱스, 인크. | T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| US20240166747A1 (en) | 2021-03-31 | 2024-05-23 | Glazosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| JP2024515189A (ja) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用 |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4377446A1 (en) | 2021-07-28 | 2024-06-05 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| JP2024534581A (ja) | 2021-09-24 | 2024-09-20 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| CA3243416A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS |
| EP4475879A1 (en) | 2022-02-08 | 2024-12-18 | Hookipa Biotech GmbH | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| CN119998330A (zh) | 2022-09-15 | 2025-05-13 | 艾维迪治疗知识产权有限公司 | 用于刺激nk细胞的多特异性抗原结合蛋白及其用途 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025021131A1 (en) * | 2023-07-25 | 2025-01-30 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Methods of treating alopecia areata and atopic dermatitis |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EP1997893A1 (en) | 1998-02-24 | 2008-12-03 | Sisters of Providence in Oregon | Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
| US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
| WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002065093A2 (en) | 2001-02-14 | 2002-08-22 | Baylor College Of Medicine | Methods and compositions of amplifying rna |
| JP4238138B2 (ja) | 2001-12-22 | 2009-03-11 | ４−アンチボディ アーゲー | 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。 |
| DE60106469T2 (de) | 2001-12-22 | 2005-10-13 | 4-Antbody AG | Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| US20060148064A1 (en) | 2002-10-25 | 2006-07-06 | Srivastava Pramod K | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| PL1674111T3 (pl) * | 2004-07-09 | 2011-04-29 | Chugai Pharmaceutical Co Ltd | Przeciwciała anty-glipikan 3 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006041763A1 (en) | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
| RU2007119989A (ru) | 2004-12-02 | 2009-01-10 | Домантис Лимитед (Gb) | Композиции, слитые конструкции и конъюгаты plad домена |
| WO2006063067A2 (en) | 2004-12-09 | 2006-06-15 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
| JP2008539693A (ja) | 2005-05-12 | 2008-11-20 | オンコセラピー・サイエンス株式会社 | 抗ｄｓｃ２抗体のエフェクター機能を用いて細胞を障害する方法 |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| AT502823B1 (de) | 2005-11-29 | 2007-06-15 | Seitz Alexander Dr | Polynukleotid-amplifikation |
| AR057253A1 (es) | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
| US20110008368A1 (en) | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
| US20080286286A1 (en) | 2006-01-13 | 2008-11-20 | Board Of Regents, The University Of Texas System | Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor |
| WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| CA2679399A1 (en) | 2007-02-27 | 2008-09-04 | Genetech, Inc. | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| HUE032735T2 (en) * | 2007-12-14 | 2017-10-30 | Bristol Myers Squibb Co | Binding molecules for the human OX40 receptor |
| EP2398498B1 (en) | 2009-02-17 | 2018-09-05 | UCB Biopharma SPRL | Antibody molecules having specificity for human ox40 |
| CN102753195A (zh) | 2009-12-07 | 2012-10-24 | 小利兰·斯坦福大学托管委员会 | 用于增强抗肿瘤抗体疗法的方法 |
| PL2609118T3 (pl) * | 2010-08-23 | 2017-07-31 | Board Of Regents, The University Of Texas System | Przeciwciała anty-OX40 i sposoby ich stosowania |
| EP2731677B1 (en) | 2011-07-11 | 2018-04-18 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to ox40 and their uses |
| KR101685262B1 (ko) | 2011-08-23 | 2016-12-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-ｏｘ４０ 항체 및 이의 사용 방법 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| HRP20201113T1 (hr) | 2013-03-15 | 2020-10-30 | Glaxosmithkline Intellectual Property Development Limited | Vežući proteini protiv lag-3 |
| RU2016142476A (ru) * | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| PH12017502013B1 (en) * | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| UY36687A (es) * | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| EP3582855A1 (en) * | 2017-02-15 | 2019-12-25 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
-
2011
- 2011-08-23 PL PL11820495T patent/PL2609118T3/pl unknown
- 2011-08-23 PE PE2013000332A patent/PE20131403A1/es active IP Right Grant
- 2011-08-23 EA EA201500204A patent/EA031849B1/ru not_active IP Right Cessation
- 2011-08-23 PE PE2017002714A patent/PE20180042A1/es unknown
- 2011-08-23 WO PCT/US2011/048752 patent/WO2012027328A2/en not_active Ceased
- 2011-08-23 ME MEP-2017-84A patent/ME02678B/me unknown
- 2011-08-23 JP JP2013526088A patent/JP5984810B2/ja active Active
- 2011-08-23 NZ NZ716369A patent/NZ716369A/en not_active IP Right Cessation
- 2011-08-23 AU AU2011293558A patent/AU2011293558B2/en not_active Ceased
- 2011-08-23 CN CN201610576880.6A patent/CN106554417B/zh not_active Expired - Fee Related
- 2011-08-23 ES ES11820495.7T patent/ES2630328T3/es active Active
- 2011-08-23 RS RS20170352A patent/RS55952B1/sr unknown
- 2011-08-23 SG SG2013013578A patent/SG187945A1/en unknown
- 2011-08-23 CN CN201180051223.5A patent/CN103221427B/zh not_active Expired - Fee Related
- 2011-08-23 MY MYPI2013000619A patent/MY171312A/en unknown
- 2011-08-23 PH PH1/2013/500354A patent/PH12013500354B1/en unknown
- 2011-08-23 BR BR112013004266A patent/BR112013004266A8/pt not_active Application Discontinuation
- 2011-08-23 ES ES15151109.4T patent/ES2649155T3/es active Active
- 2011-08-23 PT PT118204957T patent/PT2609118T/pt unknown
- 2011-08-23 US US13/818,645 patent/US9006399B2/en active Active
- 2011-08-23 HU HUE11820495A patent/HUE031371T2/en unknown
- 2011-08-23 EP EP15151109.4A patent/EP2933268B1/en active Active
- 2011-08-23 CA CA2809089A patent/CA2809089C/en not_active Expired - Fee Related
- 2011-08-23 EA EA201390278A patent/EA029793B1/ru not_active IP Right Cessation
- 2011-08-23 HR HRP20170568TT patent/HRP20170568T1/hr unknown
- 2011-08-23 SI SI201131150A patent/SI2609118T1/sl unknown
- 2011-08-23 MX MX2013002172A patent/MX339964B/es active IP Right Grant
- 2011-08-23 DK DK11820495.7T patent/DK2609118T3/en active
- 2011-08-23 KR KR1020137007252A patent/KR101704865B1/ko active Active
- 2011-08-23 NZ NZ60803311A patent/NZ608033A/en not_active IP Right Cessation
- 2011-08-23 NZ NZ629913A patent/NZ629913A/en not_active IP Right Cessation
- 2011-08-23 AP AP2013006771A patent/AP2013006771A0/xx unknown
- 2011-08-23 LT LTEP11820495.7T patent/LT2609118T/lt unknown
- 2011-08-23 EP EP11820495.7A patent/EP2609118B1/en active Active
- 2011-08-23 KR KR1020167035336A patent/KR101719118B1/ko not_active Expired - Fee Related
- 2011-08-23 SM SM20170185T patent/SMT201700185T1/it unknown
-
2012
- 2012-02-09 BR BR112014003982A patent/BR112014003982A2/pt not_active Application Discontinuation
- 2012-02-09 US US14/240,535 patent/US9163085B2/en not_active Expired - Fee Related
-
2013
- 2013-02-21 ZA ZA2013/01442A patent/ZA201301442B/en unknown
- 2013-02-22 DO DO2013000045A patent/DOP2013000045A/es unknown
- 2013-02-24 IL IL224886A patent/IL224886A/en active IP Right Grant
- 2013-02-25 CL CL2013000545A patent/CL2013000545A1/es unknown
- 2013-03-05 CO CO13044004A patent/CO6680693A2/es unknown
- 2013-03-20 CR CR20130126A patent/CR20130126A/es unknown
-
2015
- 2015-04-13 US US14/684,550 patent/US9695246B2/en not_active Expired - Fee Related
- 2015-09-08 CL CL2015002526A patent/CL2015002526A1/es unknown
- 2015-09-15 US US14/854,908 patent/US9527917B2/en not_active Expired - Fee Related
-
2016
- 2016-08-02 JP JP2016151790A patent/JP6317788B2/ja not_active Expired - Fee Related
- 2016-11-28 CL CL2016003052A patent/CL2016003052A1/es unknown
-
2017
- 2017-02-20 IL IL250691A patent/IL250691B/en not_active IP Right Cessation
- 2017-03-22 CY CY20171100363T patent/CY1118928T1/el unknown
- 2017-05-26 US US15/607,386 patent/US10196450B2/en active Active
-
2018
- 2018-12-13 US US16/219,528 patent/US10851173B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2013198490A5 (me) | ||
| MY200988A (en) | CD3 Binding Antibodies | |
| NZ718973A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP2013538057A5 (me) | ||
| JP2013506428A5 (me) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2014526898A5 (me) | ||
| JP2013502204A5 (me) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения |